Welcome to our dedicated page for Rocket Pharmaceu news (Ticker: RCKT), a resource for investors and traders seeking the latest updates and insights on Rocket Pharmaceu stock.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) is a fully integrated, late-stage biotechnology company developing investigational genetic therapies for rare and often life-threatening disorders. The RCKT news feed on Stock Titan aggregates company announcements, press releases and third-party coverage related to its AAV and lentiviral gene therapy programs.
Investors following Rocket’s news can track updates on its adeno-associated viral (AAV) cardiovascular portfolio, which includes RP-A501 for Danon disease, RP-A601 for PKP2-arrhythmogenic cardiomyopathy (PKP2-ACM) and RP-A701 for BAG3-associated dilated cardiomyopathy (BAG3-DCM). News items frequently cover clinical trial milestones, such as FDA lifting a clinical hold on the pivotal Phase 2 trial of RP-A501, preliminary Phase 1 data for RP-A601, and IND clearance and Fast Track designation for RP-A701.
The news stream also highlights developments in Rocket’s lentiviral (LV) hematology portfolio, including regulatory progress for KRESLADI (marnetegragene autotemcel; marne-cel) in severe leukocyte adhesion deficiency-I (LAD-I). Articles may discuss FDA acceptance of the resubmitted Biologics License Application (BLA), the setting of a Prescription Drug User Fee Act (PDUFA) target action date, and clinical data showing survival and infection outcomes in treated patients.
Beyond pipeline updates, RCKT news includes financial results, strategic corporate reorganization and pipeline prioritization announcements, leadership and board changes, equity inducement grants and participation in major healthcare investor conferences. By reviewing this page regularly, readers can follow how Rocket’s clinical, regulatory and corporate events may influence sentiment around RCKT stock and gain context on the company’s progress in gene therapy for rare cardiovascular and hematologic diseases.
Rocket Pharmaceuticals (NASDAQ: RCKT) has appointed Jessie Yeung as Vice President of Investor Relations and Corporate Finance. With over 15 years of experience, including a previous role at Legend Biotech (NASDAQ: LEGN), Yeung will lead investor relations and capital market strategies. CEO Gaurav Shah emphasized Yeung's expertise will enhance communication with investors as the company approaches significant milestones in gene therapy clinical programs.
Rocket Pharmaceuticals, focusing on genetic therapies for rare childhood disorders, announced positive Phase 1 results for Danon Disease, showing clinical benefits in four adults. The data indicated sustained improvement across clinical metrics. In pivotal Phase 2 trials for LAD-I, nine patients exhibited successful engraftment, with CD18 expression ranging from 26% to 87%. Six out of eight patients in the Fanconi Anemia trial demonstrated engraftment, with data expected soon. The company holds a strong cash position of $388.7 million, ensuring operational funding into the second half of 2023.
Rocket Pharmaceuticals (NASDAQ: RCKT), a clinical-stage company focused on genetic therapies for rare childhood disorders, has announced that CEO Gaurav Shah will participate in a virtual fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 10 a.m. ET. Investors can access a live audio webcast of the presentation on the company's website. Rocket's pipeline includes therapies for conditions such as Fanconi Anemia and Danon Disease, utilizing both lentiviral and adeno-associated viral vector approaches.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced key milestones for 2022 during the J.P. Morgan Healthcare Conference. Pivotal data from the LAD-I and Fanconi Anemia trials will be reported in Q2 and Q3, respectively. AAV GMP manufacturing in Cranbury, NJ is expected to begin in Q2, and data from Danon Disease pediatric cohorts is anticipated in Q3. Additionally, the initiation of pivotal Phase 2 trials for Danon Disease and PKD is planned for Q4, reflecting significant progress in advancing their genetic therapies for rare childhood disorders.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced that CEO Gaurav Shah, M.D. will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 10 at 1:30 p.m. ET. The event will be available for live audio streaming on the company’s website, with a replay accessible afterward. The company is focused on developing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease, utilizing both lentiviral vector and adeno-associated virus-based therapies.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported positive updates from its Phase 2 trials for Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), and a Phase 1 trial for Pyruvate Kinase Deficiency (PKD) at the ASH Annual Meeting. Six of eight FA patients showed evidence of engraftment and improved bone marrow mitomycin C resistance. All eight LAD-I patients exhibited durable CD18 expression crucial for survival. Additionally, two PKD patients achieved sustained normal hemoglobin levels post-treatment. A webcast event is scheduled for December 14, 2021, to discuss these findings further.
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has appointed Martin L. Wilson as General Counsel, Chief Compliance Officer, and Senior Vice President. With nearly 20 years of experience in the life sciences sector, Wilson will enhance Rocket's legal and compliance capabilities. His previous roles include General Counsel at Ichnos Sciences and Teligent, Inc. CEO Gaurav Shah emphasized that Wilson's expertise is crucial as the company aims to expand its gene therapy pipeline for rare childhood disorders. This leadership change is expected to strengthen Rocket's operational framework.
Rocket Pharmaceuticals (NASDAQ: RCKT) will host an Investor and Analyst Event on December 14, 2021 at 7:30 a.m. ET in Atlanta, featuring updates on its gene therapy programs targeting Leukocyte Adhesion Deficiency-I (LAD-I), Fanconi Anemia (FA), and Pyruvate Kinase Deficiency (PKD). Clinical data from these Phase 1 and Phase 2 trials will also be shared at the American Society of Hematology Annual Meeting (Dec. 11-14, 2021). The company is focused on developing therapies for rare childhood disorders through its innovative lentiviral vector (LVV) approach.
Rocket Pharmaceuticals (NASDAQ: RCKT) announced that CEO Gaurav Shah will participate in a fireside chat at the Evercore ISI 4th Annual HEALTHCONx Virtual Conference on December 1, 2021, at 10:55 a.m. ET. The event will highlight Rocket's efforts in advancing genetic therapies for rare childhood disorders, including Fanconi Anemia and Danon Disease. A live audio webcast will be available on Rocket's investor relations website, with a replay following the event.
Rocket Pharmaceuticals announced positive results from the Phase 1 trial of RP-A501 for Danon Disease. The investigational gene therapy showed sustained clinical benefits across key endpoints in four patients. Notably, three patients improved in NYHA class from II to I, indicating enhanced heart function, and significant reductions in BNP levels were recorded. The therapy was well tolerated at low doses, despite some adverse effects in high-dose patients. Rocket plans to transition to Phase 2 trials focusing on the low-dose cohort.